Press release
Castle Biosciences and Skin Cancer Survivor Teddi Mellencamp Arroyave Launch Campaign to Increase Awareness of Melanoma
Campaign will focus on empowering patients impacted by melanoma FRIENDSWOOD, Texas--(BUSINESS WIRE)-- Castle Biosciences, Inc. (Nasdaq: CSTL), a company
About this update from Castle Biosciences, Inc.
[{"type":"text","content":"\nCampaign will focus on empowering patients impacted by melanoma\n\n\n FRIENDSWOOD, Texas--(BUSINESS WIRE)--\nCastle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, has joined forces with television personality, wellness coach and founder of ALL IN by Teddi, host of the Two T’s in a Pod podcast and stage II melanoma survivor Teddi Mellencamp Arroyave to raise awareness around the prevention, detection and management of melanoma, the deadliest form of skin cancer. The campaign will focus on empowering patients impacted by the disease.\n\nThis press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240722546824/en/\n“When I first learned that the weird spot on my back was melanoma, I was truly in shock,” said Mellencamp Arroyave. “Yes, I tanned and laid out in the sun as a teen, but as I got older, I became more aware about taking care of my skin. Skin cancer was not anything I thought would affect me or that those choices I made when I was younger would catch up with me. After melanoma was removed from my shoulder, the 14th lesion resulting in a major surgery, the gravity of my diagnosis had become evident.\n\n\n“I want to share my story, both to encourage others to advocate for their personal health care and to educate anyone and everyone that this disease does not discriminate, looks different on every individual, and that taking care of your skin and keeping up with your skin checks is so important.”\n\n\nMelanoma will claim nearly 20 American lives each day this year, making it the most aggressive form of skin cancer.1 Castle’s DecisionDx®-Melanoma test is designed to provide personalized information about a patient’s risk of melanoma recurrence, metastasis and sentinel lymph node positivity based on the biology of their tumor. This information can help guide important decisions regarding a patient’s treatment plan and follow-up care that have been shown to improve patient survival.2,3\n\n\nMellencamp Arroyave will be sharing more about her melanoma journey in a series of conversations on Instagram (@teddimellencamp) with Aaron S. Farberg, M.D., double board-certified dermatologist, chief medical officer of Bare Dermatology in Dallas and assistant professor at the University of North Texas Health Science Center, and...